BioLife Solutions, Inc.

Equities

BLFS

US09062W2044

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
15.86 USD +4.76% Intraday chart for BioLife Solutions, Inc. -7.25% -2.40%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BioLife Solutions Completes Divestment of Global Cooling Subsidiary MT
An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc.. CI
Jefferies Initiates Coverage on BioLife Solutions With Buy Rating, $22 Price Target MT
BioLife Solutions, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : BioLife Solutions, Inc., Q4 2023 Earnings Call, Feb 29, 2024
BioLife Solutions, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Biolife Solutions Announces Preliminary Unaudited Revenue Results for Fourth Quarter and Full Year 2023 CI
Lake Street Adjusts BioLife Solutions Price Target to $15 From $25, Maintains Buy Rating MT
Transcript : BioLife Solutions, Inc., Q3 2023 Earnings Call, Nov 09, 2023
BioLife Solutions, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Casdin Capital Engages in Discussions with BioLife Solutions CI
BioLife Solutions Names New CEO; Sees 2023 Revenue at Low End of Guidance MT
BioLife Solutions, Inc. Announces Chief Executive Officer Changes CI
BioLife Solutions, Inc. Announces Management Changes CI
BioLife Solutions, Inc. Revises Earnings Guidance for the Full Year 2023 CI
BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC CI
Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating MT
Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Biolife Solutions, Inc. Provides Earnings Guidance for the Year 2023 CI
BioLife Solutions, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Stephens Adjusts BioLife Solutions Price Target to $29 From $27, Maintains Overweight Rating MT
Craig-Hallum Starts BioLife Solutions at Buy With $29 Price Target MT
Insider Sell: Biolife Solutions MT
BioLife Solutions Says SciSafe Facilities in US Received Accreditation From College of American Pathologists MT
BioLife Solutions, Inc. Launches the IntelliRate i67C Liquid Nitrogen Controlled-Rate Freezer CI
Chart BioLife Solutions, Inc.
More charts
BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to improve quality and de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets. Its products are used in basic and applied research and commercial manufacturing of biologic-based therapies. Its bioproduction tools and services are comprised of three lines: Cell processing, Freezers and thaw systems and Biostorage services. Its proprietary biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death. Its ThawSTAR line includes thawing products that control the temperature and timing of the thawing process of biologic material. It operates five storage facilities in the United States and one facility in the Netherlands.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
15.86 USD
Average target price
23.12 USD
Spread / Average Target
+45.81%
Consensus